Literature Review of Safety Event Reporting in Observational Studies: Challenges Extrapolating across Comparable Products
Nirmatrelvir/ritonavir (PAXLOVID<sup>TM</sup>, Pfizer) is an anti-infective inhibiting CYP3A4 indicated for the treatment of COVID-19 in adults at increased risk of severe COVID-19. As a newly approved product, PAXLOVID has limited safety information regarding rare events and serious adv...
| Päätekijät: | , , |
|---|---|
| Aineistotyyppi: | Artikkeli |
| Kieli: | English |
| Julkaistu: |
MDPI AG
2023-12-01
|
| Sarja: | Pharmacoepidemiology |
| Aiheet: | |
| Linkit: | https://www.mdpi.com/2813-0618/2/4/29 |